Severe Hemophilia A Clinical Trials

7 recruitingLast updated: July 25, 2026

There are 7 actively recruiting severe hemophilia a clinical trials across 14 countries. Studies span Phase 3, Phase 1, Phase 4. Top locations include Kunming, China, Jinan, China, Guangzhou, China. Updated daily from ClinicalTrials.gov.


Severe Hemophilia A Trials at a Glance

7 actively recruiting trials for severe hemophilia a are listed on ClinicalTrialsFinder across 6 cities in 14 countries. The largest study group is Phase 3 with 3 trials, with the heaviest enrollment activity in Kunming, Jinan, and Guangzhou. Lead sponsors running severe hemophilia a studies include Hangzhou Gensciences Biopharmaceutical Co., Ltd., Christoph Königs, and Octapharma.

Browse severe hemophilia a trials by phase

Treatments under study

About Severe Hemophilia A Clinical Trials

Looking for clinical trials for Severe Hemophilia A? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Severe Hemophilia A trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Severe Hemophilia A clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 3

Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.

Severe Hemophilia A
Hangzhou Gensciences Biopharmaceutical Co., Ltd.60 enrolled19 locationsNCT07684898
Recruiting
Phase 3

Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment

Severe Hemophilia A
Hangzhou Gensciences Biopharmaceutical Co., Ltd.60 enrolled24 locationsNCT07663903
Recruiting
Phase 1

A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.

Severe Hemophilia A
Pfizer15 enrolled7 locationsNCT06703606
Recruiting
Phase 4

Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study

Severe Hemophilia A
Octapharma28 enrolled18 locationsNCT05935358
Recruiting

A Study on the Bone-health Effectiveness of Applying Recombinant Factor VIII Fc (rFVIIIFc) to Patients With Hemophilia A (Prototype A)

Severe Hemophilia A Without Inhibitor
Tri-Service General Hospital (TSGH)45 enrolled1 locationNCT05981274
Recruiting
Phase 3

Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein

Severe Hemophilia A
Hangzhou Gensciences Biopharmaceutical Co., Ltd.120 enrolled28 locationsNCT06142552
Recruiting

Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab

Severe Hemophilia ASevere Hemophilia A Without InhibitorSevere Hemophilia A With Inhibitor
Christoph Königs100 enrolled1 locationNCT05802836